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Introduction
The probiotics are live microorganisms that, when 
administrated in adequate doses, confer a health ben-
efit to the host as defined by the Food and Agriculture 
Organization of the United Nations and the World 
Health Organization (FAO/WHO 2001). For this pur-
pose, lactic acid bacteria (LAB) have been used for 
a  very long time. At the beginning of the twentieth 
century, Ilja Metchnikoff suggested that the longevity 
of Bulgarians is due to consumption of fermented milk 
products (Metchnikoff 1908). Another scientist, Henry 
Tissier observed that in stools from children with diar-
rhea, only a small number of bacteria with Y-shaped 
morphology was present, while in healthy children, 
a large amount was observed (Tissier 1906). In 1965, 
Lilly and Stillwell used term “probiotic” to describe sub-
stances that were secreted by one organism and stimu-
lated the growth of another (Lilly and Stillwell 1965).
Probiotic properties have been observed in many 
genera of bacteria and fungi, but the most commonly 
used probiotics belong to the species of Lactobacillus 
and Bifidobacterium. In addition, other bacteria genera, 
like Streptococcus, Enterococcus, and Bacillus, as well as 
members of the yeast genus Saccharomyces can have 
probiotic properties (Hempel et al. 2011). The most 
common species include: Lactobacillus acidophilus, 
Lactobacillus johnsonii, Lactobacillus gasseri, Lacto­
bacillus casei, Lactobacillus rhamnosus, Lactobacillus 
plantarum, Bifidobacterium longum, Bifidobacterium 
breve, Bifidobacterium bifidum and Bifidobacterium 
infantis (Ishibashi and Yamazaki 2001). Some bacteria, 
not regularly present in the gastrointestinal tract, like 
Lactobacillus bulgaricus, Streptococcus thermophilus, 
Leuconostoc and Lactococcus species may also belong 
to the category of probiotic microorganisms and are 
usually used as starters in dairy products (Ishibashi 
and Yamazaki 2001). Most probiotic species, includ-
ing lactobacilli, Bifidobacterium, lactococci, and some 
yeasts, are classified as the “generally recognized as safe” 
(GRAS). But there are groups of organisms, like strep-
tococci, enterococci, Bacillus and other spore-forming 
bacteria, that do not possess GRAS status but have been 
used as probiotics (Snydman 2008). It should be noticed 
that not all bacteria of a given genus or species have 
probiotic features, they are assigned only to specific 
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A b s t r a c t
Probiotic bacteria have been used as a health-promoting factor for a very long time. Nowadays, products containing probiotic bacteria are 
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strains (Hill et al. 2014). The origin of the strain, resist-
ance to antibiotics, as well as the lack of pathogenicity 
determines the safety of probiotic strains (Markowiak 
and Śliżewska 2017).
The term “probiotic” can refer to the following 
products: probiotic drugs (medicinal products – live 
biotherapeutics products for human use), medical 
devices, probiotic foods (e.g. foods, food ingredients, 
dietary supplement or food for special medical pur-
poses), directly fed microorganisms (for animal use) 
and genetically modified probiotics (Venugopalan et al. 
2010). Probiotics have an annual market growth of 7% 
globally (Johnson and Klaenhammer 2014; McFarland 
2015) and are projected to grow to $65 billion in 2024 
(Global Market Insights 2017). Guidance is required to 
assess the safety of probiotics, but several issues should 
be taken into account before, i.e., a large variety of 
probiotic strains, the risks associated with the use of 
unclassified strains, and the possibility of unsurpassed 
interactions between both the strains used and the host 
and bacteria (Gueimonde et al. 2004). Probiotics may 
be responsible for systemic infections (Marteau 2001; 
Doron and Snydman 2015), excessive immune stimu-
lation in susceptible individuals (Marteau 2001; Borri-
ello et al. 2003; Doron and Snydman 2015), deleterious 
metabolic effects (Marteau 2001; Doron and Snydman 
2015) or gene transfer (Marteau 2001; Ashraf and Shah 
2011; Doron and Snydman 2015). The factors that must 
be considered in assessing the safety of probiotic prod-
ucts should include infectivity, pathogenicity, an exces-
sive immune stimulation in susceptible individuals, 
virulence factors comprising toxicity, metabolic activ-
ity and the important properties of microbes (Ishibashi 
and Yamazaki 2001). The Lactic Acid Bacteria Indus-
trial Platform has submitted reports from the European 
Union indicating that except for enterococci the risk 
of infections caused by lactic acid bacteria is very low 
(Liong 2008).
Infections
The Lactobacillus strains are present in healthy 
humans in the oral cavity, ileum and colon; moreo-
ver, they are the main microorganisms in the vagina 
(Borrielo et al. 2003). The Lactobacillus and Bifidobac­
terium strains as commensals of human microbiome 
are safe and nonpathogenic. There is no evidence that 
consumption of probiotic lactobacilli or bifidobacte-
rial strains poses the risk of infection greater than that 
related to commensal strains. The number of cases of 
infection caused by Lactobacillus or Bifidobacterium 
strains are very low and vary between 0.05–0.4% for 
infective endocarditis and bacteremia (Borrielo et al. 
2003). The translocation of bacteria may be caused by 
a weakened intestinal barrier, resulting in the passage 
of bacteria across the mucus membrane and epithe-
lium (Berg 1985). The next step is transport of micro-
organisms through the tunica propria to the mesenteric 
lymph nodes and other organs (Ishibashi et al. 2001). 
This translocation may result in bacteremia, followed 
by multiple organ failure and septicemia (Berg 1992; 
Van Leeuwen et al. 1994). Various factors such as dam-
age of the mucous membrane, disturbances in the com-
position of the intestinal microflora, or diminishing of 
the host’s immune system may stimulate the transloca-
tion of the intestinal bacteria (Ishibashi et al. 2001). In 
some clinical reports, probiotic bacteria have been iden-
tified as casual factors of dental cavities, endometritis 
(Bayer et al. 1978), urinary tract infections (Brumfitt 
et al. 1981; Dickgieber et al. 1984), meningitis (Sharpe 
et al. 1973) and spleen abscesses (Sherman et al. 1981). 
These infections can be associated with recent surgery, 
organ transplant, AIDS (Patel et al. 1994; Horwitch et al. 
1995; Land et al. 2005; Ambesh et al. 2017), valvopathy, 
diabetes mellitus, immunosuppressive cancer therapy 
or cancer with antibiotic treatment, which may con-
tribute to selection of specific microorganisms (Liong 
et al. 2008). Increased consumption of products con-
taining probiotic bacteria has not led to an increase of 
the aforementioned opportunistic infections in con-
sumers (Borrielo et al. 2003). In an epidemiological 
study of Lactobacillus bacteremia frequency in Finland, 
no correlation was found between the increased use of 
L. rhamnosus GG and the occurrence of Lactobacillus 
bacteremia during 1990–2000 (Salminen et al. 2002). 
The cases of children infections, including bacte re-
mia, caused by the Lactobacillus strains are quite rare 
and have been observed mainly in immunocompro-
mised children (Bayer et al. 1978; Kalima et al. 1996; 
Schlegel et al. 1998, Land et al. 2005), and in patients 
with neonatal sepsis and meningitis (Brughton et al. 
1983; Thompson et al. 2001), pneumonia (Sriskan-
dan et al. 1993), and also local suppurative infections 
(Brook 1996). Probiotic therapy administered to pre-
term infants and neonates should be considered care-
fully, since at birth infants do not have a fully developed 
immune system, and thereby after probiotic adminis-
tration the risk of fungemia or bacteremia significantly 
increases (Boyle et al. 2006; Marodi 2006). Lactobacillus 
bacteremia among children is very unusual, however, 
there were reports on three infants with short-bowel 
syndrome that developed bacteremia after consumption 
of L. rhamnosus GG (Kunz et al. 2004; De Groote et al. 
2005). Land et al. (2005) reported two pediatric patients 
who had ingested probiotic strain L. rhamnosus GG and 
subsequently developed bacteremia and sepsis due to 
infection with Lactobacillus species. Vahabnezhad et al. 
(2013) described a case of Lactobacillus bacteremia in 
a 17-year-old boy with ulcerative colitis after ingestion 
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of L. rhamnosus GG. The 16S rRNA genes similarity was 
99.78% between the L. rhamnosus strain isolated from 
the patient’s blood and the consumed probiotic strain. 
This information suggests that people with ulcerative 
colitis are potentially at the risk of bacteremia due to 
the Lactobacillus strains (Vahabnezhad et al. 2013). 
Analysis of the results of 74 different controlled clini-
cal trials showed that the use of probiotic and symbiotic 
in children between 0 and 18 years old was not linked 
to an increased health risk (Van den Nieuwboer et al. 
2015). L. rhamnosus and L. casei, which are commonly 
present in the commercial probiotic products, belong to 
the strains most frequently isolated during bacteremia 
caused by Lactobacillus bacteria (Salminen et al. 2004). 
These Lactobacillus species may have a greater poten-
tial to translocate and therefore, they could be more 
pathogenic than other species (Liong 2008). Other 
probiotic microorganisms directly related to bactere-
mia and endocarditis are: L. plantarum, L. paracasei, 
L. salivarius, L. acidophilus and many other lactoba-
cilli. Moreover, Lactococcus lactis, Leuconostoc, Pedio­
coccus and Bifidobacterium have also been shown to 
induce bacteremia and endocarditis (Snydman 2008). 
The studies by Harty and coworkers (Harty et al. 1993; 
Harty et al. 1994) showed that L. rhamnosus strains, 
isolated from patients with endocarditis, possess capa-
bility to aggregate platelets and to adhere to fibronec-
tin, fibrinogen and collagen. This aggregation could 
be related to proteins of the intestinal epithelium. In 
addition, L. rhamnosus and L. paracasei subsp. paraca­
sei produce enzymes that degrade human glycoproteins 
and fibrin clots, and this observation suggests that 
these molecules may participate in the development of 
infective endocarditis (Liong et al. 2008). Kochan et al. 
(2011) described a case of sepsis caused by L. rhamno­
sus in a woman with a heart valve. A bacterial translo-
cation probably occurred by a leaky intestinal barrier 
and led to heart failure in this patient (Kochan et al. 
2011). Some cases of Lactobacillus-related bacteremia 
have been reported, including L. rhamnosus GG, L. casei 
and L. acidophilus (De Groote et al. 2005; Ledoux et al. 
2006; Vahabnezhad et al. 2013). Moreover, nine cases of 
sepsis have been described, associated with S. boulardii, 
L. rhamnosus GG, Bifidobacterium breve, Bacillus sub­
tilis or combination of probiotic bacteria (Doron and 
Snydman 2015). Fungemia, caused by Saccharomyces 
cerevisiae var. boulardii is the most commonly reported 
single infection (33 reports) (Doron and Snydman 
2015). Among 89 strains from blood samples, ana-
lyzed by pulse-field gel electrophoresis, eleven strains 
had identical PFGE patterns as the probiotic strain 
L. rhamnosus GG (Salminen et al. 2004). However, the 
other studies showed that pathogenic L. rhamnosus 
GG-like strains isolated from the blood cultures, were 
phenotypically different from probiotic L. rhamnosus 
GG (Ouwehand et al. 2004). Cases of deaths of healthy 
people caused by the intake of probiotic bacteria are 
very rare. The percentage of lethal infections caused by 
Lactobacillus is very low; however, these bacteria may 
infrequently cause bacteremia or endocarditis (Doron 
and Snydman 2015). 
The probiotic strains have different antimicrobial 
susceptibility. The high doses of penicillin or ampicillin 
with or without aminoglycosides are most often used 
in treatment of lactobacilli infections. The retrospec-
tive study of 45 cases of bacteremia, demonstrated that 
100% of lactobacilli were susceptible to ampicillin, clin-
damycin and erythromycin, 96% were susceptible to 
penicillin and 67% to gentamycin (Sherid et al. 2016). 
On the other hand, bifidobacteria are generally sus-
ceptible to β-lactams, glycopeptides and erythromycin 
(Moubareck et al. 2005), while fungemias caused by 
Saccharomyces strain may be treated with fluconazole, 
amphotericin B or voriconazole (Burkhardt et al. 2005).
Stimulation of the immune system
Probiotic strains may modulate the immune res-
ponse of individuals, and this may result in the increased 
response to vaccines or allergens. Besides, these strains 
also have an effect on both cellular and humoral 
responses, and affect the secretion of cytokines (Senok 
et al. 2005). Side effects, such as fever or arthritis, can 
be caused by the presence of peptide-glycan-polysac-
charides, which are components of the bacterial cell 
wall, e.g. of the Lactobacillus genus (Marteau 2001). The 
immune system of healthy and immunocompromised 
individuals may react differently to probiotic bacteria. 
For example, probiotic bacteria may exert a stimulat-
ing effect on phagocytosis in healthy people, whereas 
for people with allergies, this effect can be opposite 
(Senok et al. 2005). The immunomodulatory effect can 
also depend on the dose of probiotic used (Tsai et al. 
2012). Despite the lack of direct reports on the pro- 
biotics harmful for immunocompromised individuals, 
it seems important to continue research on the efficacy 
and safety of probiotics (Sanders et al. 2010; Doron and 
Snydman 2015). 
Detrimental metabolic effect
Probiotic bacteria during colonization of the small 
bowel deconjugate and dehydroxylate bile salts what 
could results in diarrhea and intestinal lesions (Ago-
stoni and Salvini 2009). Since probiotic strains can 
produce bile salt hydrolase (BSH), the deconjugated 
bile salts could be accumulated, and then altered into 
harmful secondary bile acids by intestinal microbiota. 
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The accumulation of these cytotoxic compounds in 
the enterohepatic circulation could increase the risk 
of cholestasis and colorectal cancer (Tan et al. 2007). 
The harmful effects exerted by BSH on humans have 
not yet been accurately described (Ooi and Liong 2010). 
The probiotic L. acidophilus and Bifidobacterium spp., 
the strains derived from fermented milk products, may 
also convert the primary bile salts to secondary bile 
salts. If decarboxylation and dehydroxylation processes 
occur in excess, then there may be a potential risk to 
the patient’s health (Marteau et al. 1995).
Other deleterious metabolic effect is D-lactate pro-
duction by probiotic strains (Doron and Snydman 
2015). Humans produce the L(+)-isomer of lactic acid, 
while the presence of D(–)-lactate is the result of bac-
terial metabolism or transformation of L(+)-lactate by 
a bacterial DL-lactate racemase (Hove and Mortensen 
1995; Sanders et al. 2010). Some of the Lactobacillus 
strains may produce L(+)-lactic acid as well as D(–)-
lactic acid and transform one isomer into the other 
(Vitetta et al. 2017). In healthy humans, the increased 
level of D-lactic acidosis is rarely observed (Vitetta et al. 
2017), but in children with short bowel syndrome the 
blood concentration of D-lactic acid is high during an 
exacerbation of symptoms (Bongaerts 2000; Sanders 
et al. 2010). Five reports of D-lactic acidosis can be 
found in the literature (Doron and Snydman 2015), of 
which two concern the patients with short bowel syn-
drome, both proceeded by the administration of pro-
biotics (Łukasik et al. 2018). Infants may be more vul-
nerable to D-lactic acidosis, because of weaken barrier 
function of the intestinal tract and reduced ability of 
renal excretion (Sanders et al. 2010; Łukasik et al. 2018). 
In patients at risk of developing D-lactic acidosis, espe-
cially those with former bowel surgery and subsequent 
gut syndrome, and in newborns and neonates, admin-
istration of probiotics which may produce D(–)-lactate 
should be handled very carefully (Sanders et al. 2010).
Probiotic deleterious metabolic activities, such as 
degradation of mucin may also contribute to potential 
side effects after their consumption. In this case, the 
number of microorganisms that translocate through 
the small bowel is increased, possibly causing gastro-
intestinal disturbances including intestinal inflam- 
mation. One hypothesis states that the accumulation 
of probiotics in the gastrointestinal tract could result 
in increased risk of intestinal mucus degradation, but 
it was not confirmed. Ruseler-van-Embeden et al. 
(1995) conducted experiments on germ-free rats. They 
studied the degradation of mucus glycoprotein by Lac­
tobacillus casei strain GG, L. acidophilus, B. bifidum 
and lactic culture isolated from fermented products, 
but did not observe any degradation of intestinal mucus 
glycoproteins or damage of the intestinal mucus layer 
(Ruseler-van Embden et al. 1995). Moreover, Abe et al. 
(2010) did not observe translocation, damage of epi-
thelial cells or any changes of the mucosal layer in the 
ileum, cecum and colon.
Potential transfer of genes
Another aspect concerning the safety of bacte-
ria used as probiotics is the potential transfer of the 
antibiotic resistance genes between probiotics and 
other commensal or pathogenic bacteria that occur 
in the gastrointestinal tract (Teuber et al. 1999; Saly-
ers et al. 2004; Snydman 2008; Nawaz et al. 2011). It 
has been reported that over 68% of probiotic strains 
were resistant to two or more antibiotics. Moreover, 
Bacillus strains from some probiotic products display 
even a  high-level resistance. Lactic acid bacteria are 
naturally resistant to some antibiotics (Gueimonde 
et al. 2004). Many lactobacilli strains, apart from L. del­
brueckii subsp. bulgaricus, L. acidophilus, L. johnsonii 
and L. crispatus are naturally resistant to vancomy-
cin (Charteris et al. 1998; Balletti et al. 2009; Liu et al. 
2009; Shao et al. 2015; Guo et al. 2017); however, the 
genes responsible for this resistance are chromosom-
ally located and not easily transferable to other genera 
(Tynkkynen et al. 1998; Shao et al. 2015). Lactobacillus 
species are often resistant to aminoglycosides, mono-
bactams and fluoroquinolones (Zheng et al., 2017). 
Guo et al. (2017) reported that 70% of the Lactobacil­
lus strains tested were resistant to cipro floxacin. The 
resistance of LAB strains to tetracycline, erythromy-
cin, chloramphenicol, streptomycin, lincosamides and 
streptogramins may be due to the presence of plasmids 
bearing the genes encoding resistance to these antibac-
terial agents (Doron and Snydman 2015). The most 
commonly found resistance genes in Lactobacillus spe-
cies are tet(M) and erm(B), responsible for tetracycline 
and erythromycin resistance, respectively. Moreover, 
the cat gene encoding chloramphenicol acetyltrans-
ferase was also present in LAB (Fukao and Yajma 2012). 
The tet(M) genes localized in Lactobacillus strains of 
various species, derived from fermented food possess 
a high similarity to the genes present in the pathogenic 
meningococcal or Staphylococcus aureus strains (Gevers 
et al. 2003a; Gevers et al. 2003b). The resistance plas-
mids carrying the tet(M) and erm(B) genes have been 
found in L. reuteri, L. fermentum, L. acidophilus and 
L. plantarum isolated from raw meat, silage and feces 
of animals (Snydman 2008). The isolates of Leuconostoc 
and Pediococcus can accept broad host range antibiotic 
resistance plasmids from Lactococcus species (Dessart 
and Steenson 1991). Moreover, in vitro conjugation 
transfer may occur from Enterococcus to Lactococcus 
and Lactobacillus (Doron and Snydman 2015). In some 
Lactobacillus strains (e.g., L. plantarum, L. reuteri, L. fer­
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mentum) a transmission of antibiotic resistance genes to 
other LAB strains occur via the pAMβ plasmid (Schjør-
ring and Krogfelt 2011). Analysis of gene transfer from 
44 strains of L. acidophilus, 14 strains of L. delbrueckii, 
six strains of L. casei rhamnosus, five strains of L. plan­
tarum, one strain of L. helveticus, one strain of L. bre­
vis and one strain of L. fermentum, showed that only 
a single strain of L. helveticus and one L. brevis accepted 
the plasmid with low efficiency (Morelli et al. 1988). 
Sybesma et al. (2013) compared the genes from three 
bacterial isolates derived from dairy products contain-
ing the L. rhamnosus GG strains with a reference strain 
from the ATCC collection (L. rhamnosus 53103). In 
two of three strains tested, the lack of DNA fragments 
encoding 34 and 84 genes that affect the adhesion of 
these strains and their persistence in the gastrointes-
tinal tract was observed (Sybesma et al. 2013). These 
examples underline the potential for genetic variation 
in LAB and other probiotic bacteria, and suggest that 
these changes may occur in the microbial cultures used 
for commercial processes (Sanders et al. 2014). 
The risk of transfer of antibiotic resistance genes 
may be an argument against use of probiotic, for exam-
ple in aquaculture. On the other hand, some antibiotic 
resistance phenotypes, for example resistance of few 
lactobacilli strains to vancomycin (Tynkkynen et al. 
1998), or resistance represented by Streptomyces strains, 
are not easily transferable to other genera (Tan et al. 
2016). Bacterial strains used as probiotic drugs, foods 
or dairy products should be systematically controlled in 
order to detect the antibiotic resistance genes that could 
be transferable to pathogenic bacteria. According to the 
guidelines of European Food Safety Authority (EFSA) 
all bacterial strains, used as feed additives, should be 
tested to determine their sensitivity to commonly used 
antibiotics (European Food Safety Authority 2012).
Identification
The correct identification of strains is extremely 
important for safety, growth conditions and meta-
bolic properties of a given strain (FAO/WHO 2002). 
The correct classification of strains in a microbiome 
is extremely important at the time of preparation of 
the probiotic since this information is crucial for 
assessment of the stability of the strain, and to perform 
comparison with clinical isolates in the case of infec-
tion (Sanders et al. 2010). Even if the strain of pro- 
biotic bacteria is considered as safe, it still can cause 
bacteremia (Van den Nieuwboer et al. 2014) as oppor-
tunistic bacteria.
Microbiological examination of probiotic products 
showed that they might contain some microorganisms 
that were not indicated on the label (Hoa et al. 2000; 
Temmerman et al. 2002; Coeuret et al. 2004; Millazzo 
et al. 2004; Masco et al. 2005; Zawistowska-Rojek et al. 
2016). The presence of these microorganisms indicates 
an inadequate control of production or insufficient con-
trol procedures. Some of the available probiotic prod-
ucts are labeled poorly, with lack of information not 
only on the classification of the strains included, but 
also about the excipients present in product, such as 
cow’s milk protein, which may be an allergen for some 
people (Moneret-Vutrin et al. 2006; Lee et al. 2007). 
Conclusion
The major risk factor in safe applications of pro biotic 
microorganisms is the lack of knowledge on their activ-
ity. The interactions between intestinal microbes and 
the host have a major influence on the overall health 
condition. The suitable characteristics of relationships 
between probiotic structure and function would reduce 
the possibility of side effects. Generally, probiotic bac-
teria have a beneficial effect on the digestive system but 
in some cases they may facilitate the translocation or 
induce infections themselves. Due to the fact that the 
adverse effects caused by probiotics are documented, 
it is necessary to fully understand the mechanisms 
of activity of probiotic bacteria. In addition, the dif- 
ferences in activity of a single strain or a  mixture of 
strains of different species or even genera should also 
be taken into account before the probiotic use in 
humans (Sanders et al. 2010).
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